Back
“PM647 is cleared for full development after an arbitration tribunal ruled Prime Medicine owes Beam Therapeutics nothing, removing the biggest legal cloud over its lead AATD drug and its planned IND filing this quarter.”
Source
Matthew HerperX“Prime Medicine claims victory in gene-editing di…”span
“Prime Medicine claims victory in gene-editing dispute with Beam Therapeutics”
Performance
Entry$4.56
Current$4.59
Since call+0.77%
Confidence72%
How this was scored
Entry$4.56Jul 8, 2026 · 14:06 UTC · paste.trade
Current$4.59Jul 8, 2026 · 15:41 UTC · Finnhub
HorizonQ3 2026parsed as Q3-2026
Verdict bandWIN ≥ +2% · LOSS ≤ −2%
Prices are point-in-time snapshots from the named provider. The verdict compares the return since entry against the band above.